The abstract is read at the publisher; the summary is JClub's.
In the DECISION trial of 587 heart failure patients with reduced or mildly reduced ejection fraction, blinded digoxin withdrawal increased CV death or worsening HF events (42.8 vs 5.9 per 100 patient-years).
- Why it matters: It is unclear whether stopping digoxin is safe when patients are optimized on contemporary guideline-recommended therapy, leaving uncertainty about withdrawal risk.
- What they did: DECISION randomized 1001 patients to low-dose digoxin or placebo for a median 36.5 months, then 587 on active treatment underwent blinded withdrawal with 6-week in-person follow-up and adjudicated events.
- The result: After withdrawal, event rates rose markedly in the digoxin-withdrawal arm but not placebo (interaction P = .036), with more hospitalizations and urgent visits (RR 7.37, P = .012) and worsening physiologic markers.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.